Microbial conversion products of leptomycin B

Applied and Environmental Microbiology

Volumn 64, Issue 2, 1998, Pages 714-720

  Kuhnt, Michaela ^a   Bitsch, Francis ^a   Ponelle, Monique ^a   Sanglier, Jean Jacques ^a   Wang, Ying ^a   Wolff, Barbara ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS RESEARCH INSTITUTE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; LEPTOMYCIN B; REV PROTEIN;

ANTIBIOTIC BIOSYNTHESIS; ANTIFUNGAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPERGILLUS FLAVUS; BIOTRANSFORMATION; CONTROLLED STUDY; FERMENTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS 1; MASS SPECTROMETRY; NONHUMAN; PROTEIN TRANSPORT; STREPTOMYCES; VIRUS INHIBITION;

ASPERGILLUS FLAVUS; BACTERIA (MICROORGANISMS); EMERICELLA UNGUIS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; STREPTOMYCES; STREPTOMYCES RIMOSUS; STREPTOMYCES SP.;

EID: 0031938215     PISSN: 00992240     EISSN: None     Source Type: Journal    
DOI: 10.1128/aem.64.2.714-720.1998     Document Type: Article

References (18)

1. Arya, S., C. Guo, S. F. Josephs, and F. Wong-Staal. 1985. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 229:69-73.
2. Hamamoto, T., S. Gunji, H. Tsuji, and T. Beppu. 1983. Leptomycins A and B, new antifungal antibiotics. I. Taxonomy of the producing strain and their fermentation, purification and characterization. J. Antibiot. 36:639-645.
3. Hamamoto, T., H. Seto, and T. Beppu. 1983. Leptomycins A and B, new antifungal antibiotics. II. Structure elucidation. J. Antibiot. 36:646-650.
4. Hamamoto, T., T. Uozumi, and T. Beppu. 1985. Leptomycins A and B, new antifungal antibiotics. III. Mode of action of Leptomycin B on Schizosaccharomyces pombe. J. Antibiot. 38:1573-1580.
5. Kieslich, K. 1976. Classification of the transformations according to reaction type, p. 291-793. In K. Kicslich (ed.), Microbial transformations of non-steroid cyclic compounds. Georg Thieme Publishers, Stuttgart, Germany.
6. Komiyama, K., K. Okada, H. Oka, S. Tomisaka, T. Miyano, S. Funayama, and T. Umezawa. 1985. Structural study of a new antitumor antibiotic Kazusamycin. J. Antibiot. 38:220-223.
7. Komiyama, K., K. Okada, Y. Hirokawa, K. Masuda, S. Tomisaka, and I. Umezawa. 1985. Antitumor activity of a new antibiotic, Kazusamycin. J. Antibiot. 38:224-230.
8. Kuhnt, M., F. Bitsch, J. France, H. Hofmann, J. J. Sanglier, and R. Traber. 1996. Microbial biotransformation products of cyclosporin A. J. Antibiot. 49:781-787.
9. Meyer, B. E., and M. H. Malim. 1994. The HIV-1 Rev trans-activator shuttles between the nucleus and the cytoplasm. Genes Dev. 8:1538-1548.
10. Roberts, B. J., K. L. Hamelehle, J. S. Sebolt, and W. R. Leopold. 1986. In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721). Cancer Chemother. Pharmacol. 16:95-101.
11. Schreiner, E., and B. Wolff. Unpublished data.
12. Schulman, M., P. Doherry, D. Zink, and B. Arison. 1993. Microbial conversion of avermectins by Saccharopolyspora erythraea: hydroxylation at C28. J. Antibiot. 46:1016-1019.
13. Skehan, P., R. Storeng, D. Scudiero, A. Monks, J. McMahan, D. Vistica, J. T. Warren, H. Bokesch, S. Kenney, and M. R. Boyd. 1990. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82: 1107-1112.
14. Smith, R. V., and J. P. Rosazza. 1982. Microbial transformations as a means of preparing mammalian drug metabolites, p. 1-42. In J. P. Rosazza (ed), Microbial transformation of bioactive compounds, vol. 2, pt. 1. CRC Press, Inc., Boca Raton, Fla.
15. Wolff, B., G. Cohen, J. Hauber, D. Meshcheryakova, and C. Rabeck. 1995 Nucleocytoplasmic transport of the Rev protein of human immunodeficiency virus type 1 is dependent on the activation domain of the protein. Exp. Cell Res. 217:31-41.
16. Wolff, B., J. J. Sanglier, and Y. Wang. 1997. Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chem. Biol. 4:139-147.
17. Yamashita, H., S. Tsubokawa, and A. Endo. 1985. Microbial hydroxylation of compactin (ML-236B) and monacolin K. J. Antibiot. 38:605-609
18. Yoshida, E., K. Komiyama, K. Naito, Y. Watanabe, K. Takamiya, A. Okura, K. Funaishi, K. Kawamura, S. Funayama, and I. Umezawa. 1987. Anti-tumor effects of Kazusamycin B on experimental tumors. J. Antibiot. 40:1596-1604.